Abstract 739P
Background
The DESTINY-PanTumor02 trial demonstrated efficacy of HER2-directed antibody drug conjugates (ADCs) in the treatment of gynecologic malignancies, including EEA. Trial eligibility was determined utilizing HER2 IHC gastric criteria, but many institutions historically use breast criteria for IHC interpretations. As neither scoring system has been validated in gynecologic neoplasms, our study seeks to compare them in EEA.
Methods
Blinded pathology review of HER2 IHC (4B5) from 263 randomly selected EEAs was performed by two board-certified pathologists utilizing gastric and breast criteria. Results of the two scoring systems were compared (Positive [P]: intensity 3+, >10% [breast] or ≥10% [gastric] tumor cell staining, Equivocal [E]: 2+, >10% [breast] or ≥10% [gastric], Low/Negative [N]: >1+, ≤10% [breast] or <10% [gastric], or any percentage of 1+). Tumors were analyzed for ERBB2 copy number amplification by DNA (592-gene or whole exome) sequencing and statistical significance determined using unpaired T-test.
Results
Of HER2 P cases, 96% (49/51) were concordant between breast/gastric criteria, median of 13.0 copies of ERBB2. HER2 E tumors showed a lower rate of concordance with 51% (30/59) concordant cases, median of 2.5 copies of ERBB2. Of discordant HER2 E tumors, 44% (26/59) of E cases were N by breast/E by gastric (1.8 median copies, p < 0.02 vs concordant cases). HER2 N cases were 86% (155/182) concordant (1.9 median copies, p = 0.96 vs N by breast/E by gastric cases).
Conclusions
While gastric and breast criteria demonstrated 96% concordance in identifying EEAs positive for HER2 overexpression, equivocal staining was more often documented with gastric scoring. This greater frequency of equivocal results may suggest a preference for gastric criteria in the assessment of EEA, matching trial inclusion criteria where clinical benefit of HER2 ADCs has been established in patients with HER2 equivocal tumors. Table: 739P
Concordance and discordance of HER2 IHC calls by gastric and breast criteria
IHC Call | Gastric | |||
P | E | N | ||
Breast | P | 49 | 1 | 0 |
E | 1 | 30 | 1 | |
N | 0 | 26 | 155 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.G. Evans: Financial Interests, Personal, Invited Speaker: Caris Life Sciences; Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. H. Krause: Financial Interests, Institutional, Full or part-time Employment, I am a full time employee at Caris Life Sciences: Caris Life Sciences. A. Elliott: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences. C. Mathews: Financial Interests, Institutional, Research Funding: AstraZeneca, Tesaro/GSK, Astellas Pharma, Seattle Genetics, Deciphera, Moderna, Regeneron, Roche/Genentech, Pfizer, Laekna Therapeutics, EMD Serono, Merck, Genmab, Avenge Bio, Zentalis, ImmunoGen, Elucida Oncology, Artios, Volastra Therapeutics, AADI, Repare Therapeutics. S. Wei: Financial Interests, Personal, Other, board member of molecular tumor board of Caris Life Sciences: Caris Life Sciences. J. Hechtman: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer. D. Bryant: Financial Interests, Institutional, Full or part-time Employment, Senior Medical Director of Pathology: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares, Own stock and have stock options: Caris Life Sciences. M. Oberley: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck, Eisai, AstraZeneca, Seagen, Immunogenicity. P.H. Thaker: Financial Interests, Personal, Advisory Board: Merck, GSK, Seagen, Immunon, ImmunoGen, Novocure, Zentalis; Financial Interests, Personal, Other, consulting: Caris, Verastem; Financial Interests, Personal, Other, DSMB committee: Iovance; Financial Interests, Institutional, Research Grant: Merck, GSK; Financial Interests, Institutional, Coordinating PI: Zentalis, Seagen, ImmunoGen; Financial Interests, Institutional, Local PI: Verastem, Genelux. All other authors have declared no conflicts of interest.
Resources from the same session
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01
683TiP - A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Presenter: Hiromichi Nakajima
Session: Poster session 01
684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Presenter: Bhumsuk Keam
Session: Poster session 01
685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Presenter: Maria Cristina Mata Fernandez
Session: Poster session 01
687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer
Presenter: Jonathan Goldman
Session: Poster session 01
688TiP - Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Presenter: Xihui Hu
Session: Poster session 01
689TiP - A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors
Presenter: Vaia Florou
Session: Poster session 01
690TiP - HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Presenter: Thomas Powles
Session: Poster session 01
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01